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Changes in facial fat in HIV-related lipoatrophy, wasting, and weight gain measured 
by magnetic resonance imaging 
ABSTRACT 
Background: Changes in facial fat occurring over time in patients with HIV-related lipoatrophy 
have not been properly quantified. We aimed to define the longitudinal changes in facial fat 
compartments in patients with lipoatrophy and to compare these with changes accompanying 
wasting or weight gain. Method: Facial MRI scans were performed at baseline and repeated 
after a median of 10 months in 24 patients, of whom 12 had moderate to severe lipodystrophy 
continuing antiretroviral therapy, 5 lost weight, and 7 gained weight (more than 10% weight 
change). Results: Superficial facial fat decreased by a median of 5.2 mL (p = .03) in patients 
with lipoatrophy, and 8 of 12 individuals showed more than 15% decrease (all of whom were 
taking stavudine). The decrease was mainly cheek fat. Superficial facial fat decreased by 6.0 mL 
in patients with weight loss (p = .04) and increased by 20.2 mL (p = .02) in patients with 
weight gain, and changes occurred in cheek fat, temporal fat, and masseter muscle and 
temporalis muscle compartments. Conclusion: MRI can detect substantial ongoing changes in 
facial fat in patients with facial lipoatrophy. A characteristic pattern of compartmental change 
distinguishes lipoatrophy from wasting and weight recovery. MRI should be considered for use 
in clinical trials of interventions to prevent or treat lipoatrophy and may be useful for 
documenting changes in individual patients during clinical follow-up. 
